Gastric cancer is one of the top causes of death in Asia. More than 50% of gastric cancer cases happen in East Asia, and as the 3rd most common cancer after breast and lung cancer, it is important to develop prevention method to prevent and cure this disease.
Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide therapeutic vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
As part of our biotech innovation showcase at BioPharma Asia Convention, Singapore happening next 21-23 March, we invited CTO of Imugene, Dr Nick Ede to share with us his insights on this next-generation therapeutic vaccine which is currently in its clinical studies.
Q: What is your proudest pipeline in Imugene?
Ede: Our B-cell vaccine targeting HER-2/neu will commence a gastric cancer trial in Thailand, Taiwan and Hong Kong in December 2016.
Q: How is Imugene immuno-oncology product different from available drugs in the market?
Ede: Imugene’s cancer vaccine is a B-cell vaccine which stimulates a specific antibody response against the target HER-2/neu receptor.
Q: What is the biggest challenge for Imugene to operate as a biotech company in Australia?
Ede: The venture capital pool is shallow rendering large transformational capital raising difficult.
Q: How do you foresee the future of the immuno-oncology market in APAC?
Ede: Transformational. Combination therapies will revolutionise oncology treatment.
Q: In your opinion, what’s next after immuno-oncology and how do we get there?
E: Immunology-oncology is the destination. How successfully the various I-O treatments are combined and utilised will dictate the oncology landscape for the next decade and beyond.
Dr Nick Ede will speak on “Eliminating gastric cancer in Asia with B cell peptide immunotherapy – clinical update” at BioPharma Asia Convention, 21st to 23rd March 2017.
BioPharma Asia, taking place in Singapore from 22-23 March 2017 in Singapore, attracts over 1500 attendees annually. Topics from early R&D, clinical research, biomanufacturing, supply chain, market access, medical affairs and more are discussed extensively in the 3-day conference. Book now to join us.